What is RFAR in Europe?
RFAR stands for Rapid Field Alert Report. In EU terminology it’s directly linked to FSCA – Field Safety Corrective Action for medicinal products.
Definition: An urgent communication to Competent Authorities and customers regarding actions taken to reduce risk of a defective medicinal product already on the market.
Key EU Regulations Governing RFAR:
- EU GMP Part III, Chapter 8: Complaints and Product Recall
- EMA Guidance on FSCA: 48-hour notification rule
- EudraGMDP: Central portal for FSCA notifications
- Directive 2001/83/EC Article 123: Obligation to report
RFAR Europe vs FAR USA: Key Differences
| Parameter | RFAR – Europe | FAR – USA |
|---|---|---|
| Authority | EMA + National Competent Authorities NCAs | FDA – CDER District Office |
| Timeline | 48 hours to NCA after FSCA decision | 3 working days to FDA |
| Portal | EudraGMDP + National systems | FDA Form 3331, Direct to District |
| Scope | FSCA: Recall, market withdrawal, label change | Any complaint affecting quality/safety |
| Customer Notification | After NCA agreement, urgent | As part of recall strategy |
| Coordination | Multi-country, RMS led | Single country |
RFAR Timeline: The 48-Hour Rule Explained
The clock starts the moment you decide FSCA is needed. Not when investigation is complete.
Step-by-Step Timeline:
- Hour 0-4: Complaint Triage
Assess if issue impacts quality, safety, efficacy. Decide if FSCA required. - Hour 4-24: Initial Investigation + Draft FSCA
Identify affected batches, distribution, root cause hypothesis, proposed action. - Hour 24-48: NCA Notification via EudraGMDP
Submit RFAR/FSCA notification to all affected EU member states. EMA if centrally authorized. - Hour 48-72: Customer Communication
After NCA feedback, issue Field Safety Notice FSN to customers, wholesalers, hospitals. - Day 15 + Monthly: Follow-up Reports
Update NCAs on effectiveness checks, recovery rates, CAPA until closure.
Critical: “48 hours” means 2 calendar days, including weekends for urgent safety issues.
Filing RFAR via EudraGMDP
Since 2013, all FSCA/RFAR in EU must be entered in EudraGMDP – EU database for GMP and FSCA.
Information Required in EudraGMDP FSCA Form:
- Product Details: Name, strength, MA number, batch/lot
- Problem Description: Nature of defect, risk assessment
- Distribution Data: Countries, customers, quantities
- Proposed Action: Recall class, market withdrawal, quarantine
- Communication Plan: Draft FSN to customers
- Contact Person: 24/7 QA/RA contact
Tip: Assign EudraGMDP FSCA super-user in your company. Delays in login/access kill the 48hr timeline.
What Triggers a RFAR/FSCA in EU?
Any defect that could lead to risk to patients or public health:
- Critical: Sterility failure, particulate matter in injectables, wrong strength, mix-up
- Major: Label error, stability failure OOS, container closure defect
- Other: Tampering suspicion, falsified product found in supply chain
Not Triggered: Minor cosmetic issues with no safety impact. But still need complaint handling.
Field Safety Notice FSN: The Customer Communication
FSN is the letter/email sent to customers after NCA agrees to FSCA. It is part of RFAR.
FSN Must Include:
- Clear product identification + batch numbers
- Description of problem and risk to patient
- Action required: Quarantine, return, stop use
- Response form with deadline
- Contact for questions
Language: Must be in local language of each EU country. Use EMA FSN template.
Top 5 RFAR Mistakes Leading to EU GMP Non-Compliance
- Late NCA Notification
Waiting for “complete investigation”. File initial RFAR in 48hr, update later. - Incomplete Distribution Data
Not knowing which batches went to which country. Use ERP + GDP records. - No RMS Coordination
For MRP/DCP products, Reference Member State must lead. Don’t file to 27 countries separately. - Weak Effectiveness Checks
Sending FSN is not enough. Prove customers received + acted. - No Link to CAPA + APQR
RFAR should trigger CAPA and be trended in APQR/PQR.
RFAR Readiness Checklist for 2026
- ✅ 24/7 complaint hotline + escalation SOP
- ✅ Pre-approved FSCA/RFAR template
- ✅ EudraGMDP access for 2+ QA/RA users
- ✅ Distribution traceability within 2 hours
- ✅ FSN templates in all EU languages you sell in
- ✅ Mock RFAR drill done in last 12 months
- ✅ Management on call roster for weekend decisions
Conclusion: Speed + Accuracy Wins in EU
RFAR in Europe is not about paperwork. It’s about patient safety in 48 hours. The companies that survive EU inspections are those with: fast decision making, clean distribution data, and EudraGMDP ready.
Remember: In EU, you report first, investigate fully later. In US, you investigate then report.
About the Author
Mahummed Asif is a pharmaceutical QA professional with 16 years experience having sound knowledge in GMP, Product Life Cycle Management, Regulatory filing, QMS, Product Complaint Management, Change control, risk management, and USFDA audit preparation.